Zydus To Continue Mirabegron Sales

Looks To World-First Dual Shigella-Typhoid Vaccine

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list.

Zydus Is Counting On Key Products, Launches For FY26 Growth
Zydus Is Counting On Key Products, Launches For FY26 Growth (Shutterstock)

More from Earnings

More from Strategy